Phenyltetrazole derivatives as plasma kallikrein inhibitors

US12091399B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Dieter Wiedenmayer · Biberach an der Riß, DE
• Andreas Gollner · Wien, AT
• Iain Lingard · Monza, IT
• Holger Wagner · Mettenberg, DE

Key dates

• Filing date: Oct 7, 2019
• Grant date: Sep 17, 2024
• Expiry date: Oct 26, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are phenyltetrazole derivatives of formula (I), wherein A, R1, R2, X, R′, R″, and n are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the phenyltetrazole derivatives for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.